Immediate Impact
36 standout
Citing Papers
Prostate Cancer
2025 Standout
Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI
2025 Standout
Works of Jane Chang being referenced
Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).
2023
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jane Chang | 82 | 101 | 73 | 49 | 206 | |
| Joydeep Ghosh | 50 | 150 | 105 | 60 | 260 | |
| Tijani El Harroudi | 58 | 108 | 45 | 64 | 214 | |
| Ghulam Haider | 42 | 82 | 49 | 58 | 268 | |
| Prasanth Penumadu | 77 | 60 | 60 | 46 | 191 | |
| Carrie Luu | 94 | 167 | 86 | 32 | 283 | |
| Ali Arıcan | 65 | 125 | 49 | 37 | 219 | |
| Yazan Abboud | 83 | 112 | 43 | 58 | 233 | |
| Ali Murat Tatlı | 62 | 114 | 62 | 42 | 260 | |
| И. А. Покатаев | 73 | 130 | 92 | 75 | 216 | |
| Joo Young Jung | 84 | 147 | 134 | 38 | 291 |
All Works
Login with ORCID to disown or claim papers
Loading papers...